Troutman Pepper advised iECURE on the deal. iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here